Cubist Systematic Strategies’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $4.6M | Buy |
+32,743
| New | +$4.44M | 0.02% | 1013 |
|
|
2024
Q2 | – | Sell |
-58,697
| Closed | -$8.1M | – | 3671 |
|
|
2024
Q1 | $8.1M | Buy |
58,697
+30,854
| +111% | +$4.21M | 0.05% | 659 |
|
|
2023
Q4 | $3.67M | Sell |
27,843
-84,781
| -75% | -$9.76M | 0.02% | 1059 |
|
|
2023
Q3 | $12.7M | Buy |
112,624
+4,399
| +4% | +$463K | 0.09% | 277 |
|
|
2023
Q2 | $10.2M | Sell |
108,225
-25,833
| -19% | -$2.52M | 0.07% | 424 |
|
|
2023
Q1 | $13.6M | Sell |
134,058
-65,716
| -33% | -$6.84M | 0.08% | 300 |
|
|
2022
Q4 | $23.9M | Buy |
199,774
+44,176
| +28% | +$5.17M | 0.14% | 104 |
|
|
2022
Q3 | $16.5M | Buy |
155,598
+108,011
| +227% | +$11M | 0.09% | 215 |
|
|
2022
Q2 | $4.64M | Buy |
47,587
+11,291
| +31% | +$1.04M | 0.03% | 1050 |
|
|
2022
Q1 | $3.4M | Sell |
36,296
-21,546
| -37% | -$1.83M | 0.03% | 1043 |
|
|
2021
Q4 | $4.93M | Buy |
57,842
+35,567
| +160% | +$3.27M | 0.05% | 662 |
|
|
2021
Q3 | $2.14M | Buy |
22,275
+159
| +0.7% | +$15K | 0.03% | 968 |
|
|
2021
Q2 | $2.15M | Sell |
22,116
-3,481
| -14% | -$334K | 0.02% | 1035 |
|
|
2021
Q1 | $2.49M | Buy |
25,597
+11,407
| +80% | +$1.2M | 0.03% | 888 |
|
|
2020
Q4 | $1.36M | Sell |
14,190
-36,645
| -72% | -$3.54M | 0.02% | 1181 |
|
|
2020
Q3 | $4.89M | Buy |
50,835
+11,961
| +31% | +$1.38M | 0.07% | 423 |
|
|
2020
Q2 | $4.74M | Buy |
38,874
+26,461
| +213% | +$2.92M | 0.08% | 370 |
|
|
2020
Q1 | $1.07M | Sell |
12,413
-84,452
| -87% | -$8.26M | 0.03% | 783 |
|
|
2019
Q4 | $10.4M | Buy |
96,865
+78,073
| +415% | +$8.17M | 0.19% | 97 |
|
|
2019
Q3 | $1.69M | Sell |
18,792
-17,394
| -48% | -$1.63M | 0.03% | 700 |
|
|
2019
Q2 | $3.06M | Buy |
36,186
+20,506
| +131% | +$1.68M | 0.06% | 479 |
|
|
2019
Q1 | $1.38M | Buy |
15,680
+5,152
| +49% | +$431K | 0.04% | 600 |
|
|
2018
Q4 | $752K | Sell |
10,528
-39,745
| -79% | -$3.81M | 0.04% | 708 |
|
|
2018
Q3 | $6.18M | Buy |
50,273
+48,073
| +2,185% | +$5.45M | 0.34% | 36 |
|
|
2018
Q2 | $216K | Buy |
+2,200
| New | +$197K | 0.01% | 1299 |
|
|
2018
Q1 | – | Sell |
-5,119
| Closed | -$397K | – | 1981 |
|
|
2017
Q4 | $397K | Buy |
5,119
+3,383
| +195% | +$231K | 0.02% | 1057 |
|
|
2017
Q3 | $106K | Sell |
1,736
-3,565
| -67% | -$188K | 0.01% | 1613 |
|
|
2017
Q2 | $244K | Buy |
5,301
+3,193
| +151% | +$155K | 0.02% | 1175 |
|
|
2017
Q1 | $91K | Sell |
2,108
-6,671
| -76% | -$286K | 0.01% | 1410 |
|
|
2016
Q4 | $340K | Buy |
8,779
+3,766
| +75% | +$170K | 0.03% | 890 |
|
|
2016
Q3 | $254K | Sell |
5,013
-22,552
| -82% | -$1.12M | 0.02% | 1116 |
|
|
2016
Q2 | $1.25M | Sell |
27,565
-20,680
| -43% | -$952K | 0.07% | 360 |
|
|
2016
Q1 | $1.91M | Buy |
48,245
+42,539
| +746% | +$1.69M | 0.11% | 230 |
|
|
2015
Q4 | $323K | Sell |
5,706
-35,360
| -86% | -$1.8M | 0.02% | 1079 |
|
|
2015
Q3 | $1.63M | Buy |
41,066
+15,793
| +62% | +$763K | 0.08% | 342 |
|
|
2015
Q2 | $1.21M | Sell |
25,273
-17,224
| -41% | -$730K | 0.06% | 468 |
|
|
2015
Q1 | $1.69M | Buy |
42,497
+29,997
| +240% | +$1.07M | 0.08% | 348 |
|
|
2014
Q4 | $279K | Buy |
+12,500
| New | +$237K | 0.02% | 1274 |
|
Other funds holding NBIX
Cubist Systematic Strategies's NBIX Position: Q3 2025 in Review
Cubist Systematic Strategies opened a new position in Neurocrine Biosciences (NBIX) in Q3 2025: 32,743 shares worth $4.6M. The stake represents 0.02% of the portfolio and ranks #1013 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in NBIX as recently as Q1 2024.
Cubist Systematic Strategies first reported a position in NBIX in Q4 2014 and has held it in 38 quarters since. The position peaked at $23.9M in Q4 2022. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.
- Cubist Systematic Strategies held 32,743 shares of Neurocrine Biosciences worth $4.6M as of Q3 2025.
- Neurocrine Biosciences was a new Cubist Systematic Strategies position in Q3 2025.
- Neurocrine Biosciences made up 0.02% of Cubist Systematic Strategies's portfolio in Q3 2025, its #1013 holding.
- Cubist Systematic Strategies first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 38 quarters since.
- Cubist Systematic Strategies's Neurocrine Biosciences position peaked at $23.9M in Q4 2022.
- 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.